Literature DB >> 17601381

von Willebrand Factor in CHD and stroke: relationships and therapeutic implications.

Marie-Therese Cooney1, Alexandra L Dudina, Patrick O'Callaghan, Ian M Graham.   

Abstract

Atherosclerotic cardiovascular disease (CVD), which includes coronary heart disease (CHD) and stroke, is now the most common cause of death in the middle aged and elderly in all parts of the world except subSaharan Africa. The direct cause of death is frequently an acute thrombotic arterial occlusion. Because atherosclerosis is a diffuse disease, patients with CHD also have a high risk of ischemic stroke. The hemostatic process is a needed defense mechanism to control hemorrhage after injury but at same time, if overactive, may have the potential to precipitate diseases such as myocardial infarction or stroke in the setting of atherosclerosis. In approximately 1% of all patients with ischemic stroke, and in up to 4% of young adults with stroke, the major precipitant of brain ischemia is a hematologic disorder or coagulopathy that predisposes to thrombosis. von Willebrand factor (vWF) plays an important role in platelet adhesion to subendothelial structures and in the intrinsic pathway of coagulation. It is regarded as an indirect measure of endothelial dysfunction. Deficiency of vWF in von Willebrand's disease is well established. However, much less is known regarding the pathophysiologic implications of an elevated level of vWF, particularly in relation to CVD and cerebrovascular disease. The importance of vWF in the pathogenesis of this disease is poorly defined and information is limited and inconsistent. Elevated levels of vWF have been variably linked with risk of CHD; causal criteria are not fully met. Relationships with stroke risk are even less well established. Measurement of vWF adds little to risk prediction after considering the major risk factors--age, sex, smoking, raised blood cholesterol, and hypertension. vWF may have a greater role in predicting outcome in subjects with acute coronary syndromes (ACS), stroke, and perhaps atrial fibrillation. Investigation of the use of vWF level to guide treatment of ACS or stroke is ongoing; however, there is no compelling evidence to date.

Entities:  

Year:  2007        PMID: 17601381     DOI: 10.1007/s11936-007-0011-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  31 in total

1.  von Willebrand factor and coronary heart disease: prospective study and meta-analysis.

Authors:  P H Whincup; J Danesh; M Walker; L Lennon; A Thomson; P Appleby; A Rumley; G D O Lowe
Journal:  Eur Heart J       Date:  2002-11       Impact factor: 29.983

Review 2.  Role of von Willebrand factor for the onset of arterial thrombosis.

Authors:  S Goto
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

3.  Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.

Authors:  F B Smith; A J Lee; F G Fowkes; J F Price; A Rumley; G D Lowe
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

4.  Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.

Authors:  G Montalescot; J P Collet; L Lison; R Choussat; A Ankri; E Vicaut; K Perlemuter; F Philippe; G Drobinski; D Thomas
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

Review 5.  Role of von Willebrand factor in arterial thrombosis. Studies in normal and von Willebrand disease pigs.

Authors:  T C Nichols; D A Bellinger; R L Reddick; M S Read; G G Koch; K M Brinkhous; T R Griggs
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

6.  von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.

Authors:  A J Catto; A M Carter; J H Barrett; J Bamford; P J Rice; P J Grant
Journal:  Thromb Haemost       Date:  1997-06       Impact factor: 5.249

7.  Tissue distribution of factor VIII gene expression in vivo--a closer look.

Authors:  M J Hollestelle; T Thinnes; K Crain; A Stiko; J K Kruijt; T J van Berkel; D J Loskutoff; J A van Mourik
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

8.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

9.  Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes.

Authors:  Kaeng W Lee; Gregory Y H Lip; Muzahir Tayebjee; William Foster; Andrew D Blann
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

10.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more
  4 in total

1.  Deficiency in core circadian protein Bmal1 is associated with a prothrombotic and vascular phenotype.

Authors:  Payaningal R Somanath; Eugene A Podrez; Juhua Chen; Yi Ma; Kandice Marchant; Marina Antoch; Tatiana V Byzova
Journal:  J Cell Physiol       Date:  2011-01       Impact factor: 6.384

2.  Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction.

Authors:  Andreja Sinkovic
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

3.  Interaction between vWF levels and aspirin resistance in ischemic stroke patients.

Authors:  Yıldız Arslan; Tahir Kurtuluş Yoldaş; Yaşar Zorlu
Journal:  Transl Stroke Res       Date:  2013-04-25       Impact factor: 6.829

4.  Effect of continuous positive airway pressure on day/night rhythm of prothrombotic markers in obstructive sleep apnea.

Authors:  Roland von Känel; Loki Natarajan; Sonia Ancoli-Israel; Paul J Mills; Tanya Wolfson; Anthony C Gamst; José S Loredo; Joel E Dimsdale
Journal:  Sleep Med       Date:  2012-10-01       Impact factor: 3.492

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.